NFXBio: Why C2i is the World’s First Platform for Cancer Intelligence

In this episode, James Currier and Omri Amirav-Drory delve into synthetic biology and tech bio, introducing guest Asaf Zviran, CEO of C2I. They discuss the impact of tech bio on industries, strategies for hiring and fundraising in a virtual world, and the balance between science and business in startups. They also explore the future of cancer treatment and provide valuable advice for startup founders.